Best Tools for Gut Health & Weight Loss | Dr. Chris Thompson

I wanted to begin with the actual digestive tube. People hear microbiome, gut-brain axis, and GLP drugs, but the basic journey of food still matters: what makes us want to eat, what stops that drive, and what these compartments are doing.

The gut is not merely plumbing. It digests, but it’s also an endocrine organ—people call it a second brain—and each section has an assignment. The esophagus moves food down; the stomach expands, churns, acidifies, and releases a meal gradually. The small bowel absorbs most calories, while the colon works with microbes, water handling, short-chain fatty acids, and satiety hormones.

When swallowing feels blocked, get it evaluated. Reflux can scar and narrow the esophagus, achalasia can prevent its lower end from relaxing, and a Zenker diverticulum can catch food that comes back up. Food reaching the nose may sound funny, but aspiration into the lungs is not.

We’re good at treating bowel movements as a health readout in babies and puppies, then everybody goes silent. But frequency, consistency, and changes really are useful information.

A rough rule is no more than three bowel movements daily and not beyond three days without one. Formed stool is the goal; hard pebbles can suggest constipation and inadequate fiber. Very dark, sticky, tar-like stool can indicate bleeding and needs medical attention.

I started using powdered psyllium expecting bloat. Instead, things felt more normal, including after meals. People hear fiber and imagine gas, when the bigger message is that it helps create a healthier gut environment.

Exactly: feed the microbes, or they start feeding on you. Fiber supports diversity; without enough, microbes can draw on the mucus layer. Then you have less butyrate, which helps colon cells and the junctions between gut cells. It’s not simply about regularity.

That raises fasting. If the microbiome uses the gut lining during food-free periods, should someone with gut issues avoid time-restricted eating?

I don’t see that as a major concern. Time-restricted eating likely has benefits beyond that theoretical risk, including time for insulin to come down. Timing is still evolving, but eating earlier and beginning the fasting window later may be preferable to assuming breakfast is automatically the wrong meal. Fermented foods—kefir, kimchi, sauerkraut—also help support a healthier microbial community alongside fiber.

We also cleared up the oversimplification around ulcers. H. pylori was a remarkable discovery, but people have long observed that stress matters too.

H. pylori absolutely causes ulcers and should be treated, but ulcer biology can involve several hits: acid, stress-related acid production, smoking, impaired small-vessel blood flow, and altered anatomy after bypass. One established cause does not erase every other mechanism.

Then we got to the question hanging over metabolic health: GLP-one drugs. They’ve helped huge numbers of people, but are they the complete answer for obesity?

I’m grateful we have them. Obesity has serious consequences, and we were not doing enough before these drugs. But they’re not perfect: people stop because of injections, nausea, dose intolerance, cost, or ordinary adherence problems. They’re powerful tools, not a finished solution.

Muscle loss is the major concern, from subtle appearance changes to true sarcopenia. Resistance training matters with medication, surgery, or endoscopic treatment because it tells the body that muscle is needed. Cycling on and off a GLP-one can be especially problematic: regained weight tends to be fat rather than the lean mass lost.

Hunger is a network, not just GLP-one. Ghrelin rises from the upper stomach; after food moves onward, CCK, PYY, GIP, and GLP-one contribute to fullness. Leptin is more like a long-term thermostat, though resistance complicates obesity. That’s why forcing one lever may not be ideal.

Highly processed foods push that system in the wrong direction. In a tightly controlled study, people offered processed foods ate roughly five hundred extra calories a day versus whole foods. They’re easier to eat and digest, often lower in fiber, and likely don’t help the microbiome.

I’d rather find metabolic dysfunction before A-one-C shows advanced trouble. A continuous glucose monitor can show meal responses, and fasting insulin can flag risk earlier in some people. I worry about excess calorie exposure, rising insulin, fat accumulating in liver and muscle, then insulin resistance and reduced metabolic flexibility.

I like thinking of these as voluntary data, not an invitation to panic over a grape. Waiting until the standard abnormal marker appears can mean we missed an earlier window.

More information needs good interpretation. A CGM tells you something about glucose, not whether every food choice is healthy. Use it with diet quality, activity, fasting insulin, lipids, and body composition—not as permission for junk food that happens not to spike one measurement.

My work moved toward endoscopic metabolic therapies because we learned bariatric operations alter physiology, not just restriction or malabsorption. We can now work through the mouth: endoscopic sleeve gastroplasty folds the stomach for earlier stretch signaling and slower emptying; other approaches target the duodenum or small bowel to strengthen hormone responses. The goal is the least intervention that matches the person’s biology.

That feels like the larger lesson: don’t blast one pathway if smaller pushes on several can get a better result with fewer downsides. A lower drug dose plus a procedure, nutrition, and training may beat treating biology like a single switch.

Diet and exercise alone can run into a defended weight range—hunger rises, satiety falls, energy expenditure drops—but fundamentals never become irrelevant. With a GLP-one, procedure, or surgery, people still need fiber, better food quality, resistance work, zone-two activity, and high-intensity training when appropriate.

I’m excited by AI as a coach during procedures. It can identify structures, flag blood vessels, assess stitches, and shorten the learning curve. The clinician still uses judgment, but pattern recognition from thousands of procedures can make difficult endoscopic work safer.

The future may be more targeted still. Early gene-therapy work is trying to make pancreatic beta cells release GLP-one in a nutrient-responsive way alongside insulin, rather than bathing the body in huge doses. It’s early, but restoring physiology at the right place and time is compelling.

I’m grateful you’re a tinkerer who keeps the patient in view. You return to the underlying problem rather than settling for a partial fix, and you’re generous about crediting the teams behind the work.

Thank you. It really is a team effort. Innovation is never one person working alone; I’ve been fortunate to have remarkable people helping move these ideas forward.